CA
Candel Therapeutics, Inc.
CADL · NASDAQ
$11.85 +5.05% (+$0.57)
1M -7.85%
Market Cap $868.3M
P/E Ratio -
Div. Yield -
ROE 89.38%
Bulios Fair Price
$8.27
30.2% downside
Current Price
$11.85
Undervalued Fair Value Overvalued
According to Bulios Fair Price, CADL is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
14 /100
Expensive P/B 6.88x
EV/EBITDA N/A
P/S N/A
Growth
39 /100
Stable Book val. growth 2.86%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
0 /100
Poor ROE 89.38%
ROA 42.53%
Asset turnover 0.00x
Debt
66 /100
Moderate Current ratio 16.09x
Int. coverage -17.77x
Debt/Equity 0.39x
Stability
19 /100
Unstable EPS volatility 712.08%
Profitable years 0
Beta -0.47x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CADL
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Paul-Peter Tak
Employees
55
Headquarters
Needham
Upcoming events
12 NOV
Earnings
Upcoming earnings report